Live Breaking News & Updates on Formycon

Stay updated with breaking news from Formycon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

EQS-News: Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara1 (ustekinumab) Seite 1

02.02.2023 - EQS-News: Formycon AG / Key word(s): Agreement/Alliance Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara1 (ustekinumab) 02.02.2023 / 08:00 CET/CEST The issuer is solely . Seite 1 ....

United States , Fresenius Kabi , Latin America ,

EQS-Adhoc: Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase Seite 1

02.02.2023 - EQS-Ad-hoc: Formycon AG / Key word(s): Capital Increase/Corporate Action Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase 02-Feb-2023 / 07:30 CET/CEST Disclosure of an inside . Seite 1 ....

Ewvy Formycon Or Company , Management Board , Supervisory Board , Active Ownership Capital , New Share , New Shares ,

Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)

EQS-Ad-hoc: Formycon AG / Key word: Agreement/Alliance

Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1
01-Feb-2023 / 17:40. | February 1, 2023 ....

United States , Johnson Stelara , Fresenius Kabi , Corporate Communications , Market Scale Of The Frankfurt Stock Exchange , Latin America , Middle East , Securities Act , Open Market , Frankfurt Stock Exchange , Manager Corporate Communications , Formycon Ag Stock Exchange , Press Release , O Fyb De000a1ewvy8 ,

EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea1, in the United States Seite 1

09.01.2023 - EQS-Ad-hoc: Formycon AG / Key word(s): Agreement/Alliance Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea1, in the United States . Seite 1 ....

United States , Klinge Biopharma , Coherus Biosciences , Klinge Biopharma Gmbh , Coherus Biosciences Inc , Drug Administration , Term Sheet , Biologics License Application ,

Formycon Announces Details For Pembrolizumab Biosimilar - Life Sciences, Biotechnology & Nanotechnology

This week Formycon AG ("Formycon") announced details of its previously undisclosed pipeline project for FYB206, Formycon's biosimilar of KEYTRUDA (pembrolizumab). ....

Scientific Advice Meetings , Life Sciences , Life Sciences , Iotechnology Amp Nanotechnology , Intellectual Property ,